Arrowhead Pharmaceuticals stock
ARWRNASDAQArrowhead Pharmaceuticals, Inc., HealthcareISIN US04280A1007
32Score 32 out of 100, Weak
Price and trend
27 / 100
Price history
+14% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 34% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 25).
The price is 47% below its 52-week high. Largest decline in 20 years: 98% (May 2007 to December 2016).
Chart figures for advanced users
- SMA 50$64.10
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$71.19
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)25
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$38.09
- The lowest closing price of the last twelve months.
- Resistance$89.59
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Arrowhead Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $6.66B, is number 58 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $829.45M (up 23,258.2% year on year) and a loss of $1.63M.
- For fiscal 2026, analysts expect on average revenue of $464.24M (down 44%) and adjusted earnings per share of −$3.52.
Show more
- MEQIRI Score 32 out of 100 (Weak): rank 668 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 56.6% a year since 2020, Biotechnology median 19.7%.Growth 70
- High return on capitalReturn on invested capital 36.8% in fiscal 2025, Biotechnology median −24.3%.
- More cash than debtCash $1.6B, financial debt $864.07M.
Weaknesses
- DilutionShare count up 33% since 2020.Capital allocation 18
- Loss-makingLoss of $319.95M over the last 12 months.Fundamentals 17
- Interest barely coveredOperating profit covers interest only 1.6 times.Stability 38
Its standout strength is growth, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Revenue has grown strongly since 2006, at around 46% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating 12%, net 0%. Last 12 months: net −48%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 12 Nov 2026today
- Last reported
- 4 Aug 2026EPS reported −$1.36 (expected −$1.28)below expectations
Analyst estimates
Analysts have raised their 2028 earnings estimate by 4.8% since 15 Oct 2026.
- Earnings per share
- −$4.86−1.2%
- Revenue
- $330.13M−2.0%
- Earnings per share
- −$2.81+4.8%
- Revenue
- $666.07M−9.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +1.0%No financial guidance: more trial data are scheduled for September and the fourth quarter, and Phase III data for another drug are expected in the third quarter of 2027.
“The Zodasiran YOSEMITE Phase III study in HoFH patients is fully enrolled, and we expect to have data in Q3 2027 and hopefully file an NDA by the end of 2027.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $1.19M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Arrowhead Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 32
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- ImmunovantIMVT $7.64B45
- Bachem HoldingBANB.SW $7.3B58
- ImmunityBioIBRX $7.1B38
- Caris Life SciencesCAI $7.02B58
- Kodiak SciencesKOD $6.87B43
- Samsung Epis Holdings0126Z0.KS $6.58B41
- CG OncologyCGON $6.49B41
- BioconBIOCON.NS $6.4B41
ETFs that hold Arrowhead Pharmaceuticals
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 2.28% | 0.50% | €127.06M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.07% | 0.49% | €318.39M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.79% | 0.40% | €1.49B |
Show 5 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.53% | 0.35% | €1.21B |
| iShares Ageing Population UCITS ETF2B77 | 0.39% | 0.40% | €807M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.24% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.11% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.07% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Sep 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 8 May 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.